2018 FDA Tides Harvest

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2019 Apr 10

PMID 30959752

Citations 17

Authors

Danah Al Shaer

Othman Al Musaimi

Fernando Albericio

Beatriz G de la Torre

Affiliations

Soon will be listed here.

Abstract

In 2018, the United States Food and Drug Administration (FDA) approved a total of 59 new drugs, three of them (5%) are TIDES (or also, -tides), two oligonucleotides and one peptide. Herein, the three TIDES approved are analyzed in terms of medical target, mode of action, chemical structure, and economics.

Citing Articles

New approach methodologies to assess wanted and unwanted drugs-induced immunostimulation.

Bettinsoli V, Melzi G, Marchese I, Pantaleoni S, Passoni F, Corsini E Curr Res Toxicol. 2025; 8:100222.

PMID: 40027547 PMC: 11872130. DOI: 10.1016/j.crtox.2025.100222.

Porous silicon and silica carriers for delivery of peptide therapeutics.

Yan J, Siwakoti P, Shaw S, Bose S, Kokil G, Kumeria T Drug Deliv Transl Res. 2024; 14(12):3549-3567.

PMID: 38819767 PMC: 11499345. DOI: 10.1007/s13346-024-01609-7.

2023 FDA TIDES (Peptides and Oligonucleotides) Harvest.

Al Shaer D, Al Musaimi O, Albericio F, de la Torre B Pharmaceuticals (Basel). 2024; 17(2).

PMID: 38399458 PMC: 10893093. DOI: 10.3390/ph17020243.

Biocompatible strategies for peptide macrocyclisation.

He J, Ghosh P, Nitsche C Chem Sci. 2024; 15(7):2300-2322.

PMID: 38362412 PMC: 10866349. DOI: 10.1039/d3sc05738k.

Strategic Approaches to Improvise Peptide Drugs as Next Generation Therapeutics.

Barman P, Joshi S, Sharma S, Preet S, Sharma S, Saini A Int J Pept Res Ther. 2023; 29(4):61.

PMID: 37251528 PMC: 10206374. DOI: 10.1007/s10989-023-10524-3.

References

Kam B, Teunissen J, Krenning E, de Herder W, Khan S, van Vliet E . Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012; 39 Suppl 1:S103-12. PMC: 3304065. DOI: 10.1007/s00259-011-2039-y. View

Rowczenio D, Noor I, Gillmore J, Lachmann H, Whelan C, Hawkins P . Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014; 35(9):E2403-12. DOI: 10.1002/humu.22619. View

Banerjee S, Pillai M, Knapp F . Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev. 2015; 115(8):2934-74. DOI: 10.1021/cr500171e. View

Hawkins P, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr O . Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015; 47(8):625-38. PMC: 4720049. DOI: 10.3109/07853890.2015.1068949. View

Butler J, Chan A, Costelha S, Fishman S, Willoughby J, Borland T . Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis. Amyloid. 2016; 23(2):109-18. PMC: 4898164. DOI: 10.3109/13506129.2016.1160882. View

Mullard A . 2016 FDA drug approvals. Nat Rev Drug Discov. 2017; 16(2):73-76. DOI: 10.1038/nrd.2017.14. View

de la Torre B, Albericio F . The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type. Molecules. 2017; 22(3). PMC: 6155368. DOI: 10.3390/molecules22030368. View

Chakradhar S . A protein puzzle. Nat Med. 2017; 23(3):266-269. DOI: 10.1038/nm0317-266. View

Adams D, Suhr O, Dyck P, Litchy W, Leahy R, Chen J . Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol. 2017; 17(1):181. PMC: 5594468. DOI: 10.1186/s12883-017-0948-5. View

10.

Mullard A . 2017 FDA drug approvals. Nat Rev Drug Discov. 2018; 17(2):81-85. DOI: 10.1038/nrd.2018.4. View

11.

de la Torre B, Albericio F . The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2018; 23(3). PMC: 6017390. DOI: 10.3390/molecules23030533. View

12.

Al Musaimi O, Al Shaer D, de la Torre B, Albericio F . 2017 FDA Peptide Harvest. Pharmaceuticals (Basel). 2018; 11(2). PMC: 6027222. DOI: 10.3390/ph11020042. View

13.

Yang J . Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis. Expert Rev Clin Pharmacol. 2019; 12(2):95-99. DOI: 10.1080/17512433.2019.1567326. View

14.

Mullard A . 2018 FDA drug approvals. Nat Rev Drug Discov. 2019; 18(2):85-89. DOI: 10.1038/d41573-019-00014-x. View

15.

de la Torre B, Albericio F . The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2019; 24(4). PMC: 6412490. DOI: 10.3390/molecules24040809. View

16.

Fire A, Xu S, Montgomery M, Kostas S, Driver S, Mello C . Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998; 391(6669):806-11. DOI: 10.1038/35888. View